Details of Disease

Disease Name

Hyperphosphatemia

hyperphosphatemia (disease); hyperphosphatemia

Definition

Abnormally high level of phosphate in the blood.

Disease Hierarchy

DIS4VC27: Phosphorus metabolism disease

DISHW3R3: Hyperphosphatemia

Disease Identifiers

MONDO ID

MONDO_0000328

MESH ID

D054559

UMLS CUI

C0085681

MedGen ID

39326

HPO ID

HP:0002905

SNOMED CT ID

20165001

General Information of Disease (ID: DISHW3R3)

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 1 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Ferric citrate	DM85PUZ	Approved	Small molecular drug	[1]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 4 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
COASY	TT4YO0Z	Strong	Genetic Variation	[2]
PTH1R	TTFPD47	Strong	Genetic Variation	[3]
SLC34A2	TTQPZTM	Strong	Biomarker	[4]
SLC9A3	TTFZVPO	Definitive	Biomarker	[5]
------------------------------------------------------------------------------------

This Disease Is Related to 1 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC34A3	DTKS517	Strong	Biomarker	[3]
------------------------------------------------------------------------------------

This Disease Is Related to 6 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
GALNT3	OT7M67WT	Limited	Altered Expression	[6]
KL	OTD4VWU6	Limited	Genetic Variation	[7]
KAT8	OT5LPQTR	Strong	Biomarker	[8]
PIK3C2A	OTFBU4GD	Strong	Biomarker	[9]
PTRH1	OTOAOS93	Strong	Biomarker	[10]
SMPD3	OTHQBETH	Strong	Altered Expression	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 DOT(s)

References

1	Ferric citrate FDA Label
2	Diagnosis and management of congenital hypothyroidism associated with pseudohypoparathyroidism.Horm Res Paediatr. 2015;83(2):111-7. doi: 10.1159/000369492. Epub 2015 Jan 9.
3	In vivo evidence for an interplay of FGF23/Klotho/PTH axis on the phosphate handling in renal proximal tubules.Am J Physiol Renal Physiol. 2018 Nov 1;315(5):F1261-F1270. doi: 10.1152/ajprenal.00650.2017. Epub 2018 Jul 11.
4	The role of the gastrointestinal tract in phosphate homeostasis in health and chronic kidney disease.Curr Opin Nephrol Hypertens. 2013 Jul;22(4):481-7. doi: 10.1097/MNH.0b013e3283621310.
5	Tenapanor: First Approval.Drugs. 2019 Nov;79(17):1897-1903. doi: 10.1007/s40265-019-01215-9.
6	A Mutation in the Dmp1 Gene Alters Phosphate Responsiveness in Mice.Endocrinology. 2017 Mar 1;158(3):470-476. doi: 10.1210/en.2016-1642.
7	A Novel Heterozygous Deletion Variant in KLOTHO Gene Leading to Haploinsufficiency and Impairment of Fibroblast Growth Factor 23 Signaling Pathway.J Clin Med. 2019 Apr 12;8(4):500. doi: 10.3390/jcm8040500.
8	Treatment of hyperphosphatemia based on specific interactions between phosphorus and Zr(iv) active centers of nano-MOFs.Chem Sci. 2018 Jul 23;9(38):7483-7487. doi: 10.1039/c8sc02638f. eCollection 2018 Oct 14.
9	A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor.Invest New Drugs. 2019 Apr;37(2):282-290. doi: 10.1007/s10637-018-0648-z. Epub 2018 Aug 13.
10	High-serum phosphate and parathyroid hormone distinctly regulate bone loss and vascular calcification in experimental chronic kidney disease.Nephrol Dial Transplant. 2019 Jun 1;34(6):934-941. doi: 10.1093/ndt/gfy287.
11	Barley--glucans reduce systemic inflammation, renal injury and aortic calcification through ADAM17 and neutral-sphingomyelinase2 inhibition.Sci Rep. 2019 Nov 28;9(1):17810. doi: 10.1038/s41598-019-54306-8.